Mod­er­na goes af­ter Al­ny­lam, fil­ing coun­ter­claims in Spike­vax patent suit

Mod­er­na has gone on the of­fen­sive in its patent feud against Al­ny­lam, fil­ing two coun­ter­claims against the RNAi drug de­vel­op­er af­ter Al­ny­lam’s patent suit.

The two 44-page doc­u­ments, filed last Wednes­day in Delaware dis­trict court, ac­cus­es Al­ny­lam of “base­less­ly” look­ing to prof­it off Mod­er­na’s mul­ti-bil­lion-dol­lar block­buster Covid-19 vac­cine and asked the court to de­clare Al­ny­lam’s patent in­valid. Mod­er­na al­so said Al­ny­lam has no claim against Mod­er­na “to the ex­tent Mod­er­na used or man­u­fac­tured Spike­vax for the Gov­ern­ment and ‘with the au­tho­riza­tion or con­sent of the Gov­ern­ment’ un­der 28 U.S.C. § 1498.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER